598 results on '"Gill, Harinder"'
Search Results
2. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
3. Rashtriya swsthya bima yojna in India- Implementation and impact
4. A study of accessibility, availability and quality of health services in Punjab
5. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction
6. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021
7. Eosinophilic Disorders and Systemic Mastocytosis
8. Management of Relapsed or Refractory AML
9. In the Pipeline: Emerging Therapy for CML
10. Prognostic Indicators in MDS and CMML
11. Molecular Landscape and Personalized Prognostic Prediction of MPNs
12. Treatment Algorithm for Primary and Secondary Myelofibrosis
13. In the Pipeline: Emerging Therapy for MDS and MDS/MPN
14. Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?
15. Modern Classification of Acute and Chronic Leukemias: Integrating Biology, Clinicopathologic Features, and Genomics
16. In the Pipeline—Emerging Therapy for ALL
17. Next-Generation FLT3 Inhibitors for the Treatment of FLT3-Positive AML
18. Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation
19. Frontline Management of Acute Promyelocytic Leukemia
20. Prognostic Models for Primary and Secondary Myelofibrosis
21. Clonal Hematopoiesis and Its Functional Implications in MDS/AML
22. Role of IDH1/IDH2 Inhibitors in AML
23. Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
24. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
25. Undiagnosed Hypertension in Vancouver’s Punjabi Sikh Community: A Cross-Sectional Study
26. Prioritising the psychosocial needs of young oncology patients: a call for comprehensive care
27. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
28. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
29. CD3+CD4+ lymphoid neoplasm: diagnostic clues for plasmablastic lymphoma instead of peripheral T-cell lymphoma
30. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
31. Responsiveness of Output & Prices to Monetary & Fiscal Shocks in India
32. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study
33. Clinical delineation, sex differences, and genotype–phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2
34. Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy
35. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report
36. Bomedemstat as an investigative treatment for myeloproliferative neoplasms
37. Rethinking Palliative Care in Psychiatry
38. POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
39. MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
40. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
41. Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II
42. ORAL arsenic trioxide to combat acute promyelocytic leukaemia
43. RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit—successes and challenges
44. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis
45. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment
46. Congenital heart defects : a clinical and genetic analysis
47. Rheumatology and palliative care: needs and opportunities
48. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
49. Complexities in delivering end-of-life care in accordance with patient desires that have been documented
50. Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.